Načítá se...
A Pilot Study of Bevacizumab and Interferon-α2b in Ocular Melanoma
OBJECTIVES: We hypothesized that administration of bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor, in combination with high-dose interferon-alpha2b (IFN-α2b), an inhibitor of basic fibroblast growth factor, would have clinical activity in patients with metasta...
Uloženo v:
| Vydáno v: | Am J Clin Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4294796/ https://ncbi.nlm.nih.gov/pubmed/20458209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3181d2ed67 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|